Akebia Therapeutics Inc. [NASDAQ: AKBA] surged by $0.55 during the normal trading session on Monday and reaching a high of $5.14 during the day while it closed the day at $5.06. The company report on February 8, 2021 that Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced plans to release its financial results for the fourth quarter and full-year 2020 ended December 31, 2020, on Thursday, February 25, 2021, before the opening of the financial markets.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, February 25, 2021 to discuss its fourth quarter and full-year 2020 financial results and recent business highlights. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 5455117. The call will also be webcast live and can be accessed via the Investors section of the Company’s website at http://ir.akebia.com.
Akebia Therapeutics Inc. stock has also gained 48.60% of its value over the past 7 days. However, AKBA stock has inclined by 103.21% in the 3 months of the year. Over the past six months meanwhile, it has lost -53.92% and gained 80.71% year-on date.
The market cap for AKBA stock reached $627.64 million, with 143.32 million shares outstanding and 142.95 million shares in the current float. Compared to the average trading volume of 6.00M shares, AKBA reached a trading volume of 14654606 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Akebia Therapeutics Inc. [AKBA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AKBA shares is $7.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AKBA stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Akebia Therapeutics Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on January 29, 2021. While these analysts kept the previous recommendation, Needham dropped their target price from $18 to $15. The new note on the price target was released on November 14, 2019, representing the official price target for Akebia Therapeutics Inc. stock. Previously, the target price had yet another drop from $19 to $17, while H.C. Wainwright kept a Buy rating on AKBA stock. On July 11, 2019, analysts decreased their price target for AKBA shares from 23 to 21.
The Average True Range (ATR) for Akebia Therapeutics Inc. is set at 0.33, with the Price to Sales ratio for AKBA stock in the period of the last 12 months amounting to 2.04. The Price to Book ratio for the last quarter was 2.28, with the Price to Cash per share for the same quarter was set at 2.17.
AKBA stock trade performance evaluation
Akebia Therapeutics Inc. [AKBA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 48.60. With this latest performance, AKBA shares gained by 64.82% in over the last four-week period, additionally sinking by -53.92% over the last 6 months – not to mention a drop of -40.75% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AKBA stock in for the last two-week period is set at 79.67, with the RSI for the last a single of trading hit 84.32, and the three-weeks RSI is set at 74.91 for Akebia Therapeutics Inc. [AKBA]. The present Moving Average for the last 50 days of trading for this stock 3.22, while it was recorded at 4.18 for the last single week of trading, and 6.86 for the last 200 days.
Akebia Therapeutics Inc. [AKBA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc. [AKBA] shares currently have an operating margin of -85.46 and a Gross Margin at +56.61. Akebia Therapeutics Inc.’s Net Margin is presently recorded at -83.48.
Return on Total Capital for AKBA is now -49.62, given the latest momentum, and Return on Invested Capital for the company is -49.32. Return on Equity for this stock declined to -54.27, with Return on Assets sitting at -29.74. When it comes to the capital structure of this company, Akebia Therapeutics Inc. [AKBA] has a Total Debt to Total Equity ratio set at 27.44. Additionally, AKBA Total Debt to Total Capital is recorded at 21.53, with Total Debt to Total Assets ending up at 14.05. Long-Term Debt to Equity for the company is recorded at 26.18, with the Long-Term Debt to Total Capital now at 20.54.
Reflecting on the efficiency of the workforce at the company, Akebia Therapeutics Inc. [AKBA] managed to generate an average of -$776,831 per employee. Receivables Turnover for the company is 12.07 with a Total Asset Turnover recorded at a value of 0.36.Akebia Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 2.20.
Earnings per share (EPS) analysis for Akebia Therapeutics Inc. [AKBA] stock
With the latest financial reports released by the company, Akebia Therapeutics Inc. posted -0.79/share EPS, while the average EPS was predicted by analysts to be reported at -0.47/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -68.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AKBA.
Akebia Therapeutics Inc. [AKBA]: Insider Ownership positions
There are presently around $508 million, or 75.40% of AKBA stock, in the hands of institutional investors. The top three institutional holders of AKBA stocks are: STATE STREET CORP with ownership of 15,340,471, which is approximately 206.073% of the company’s market cap and around 1.09% of the total institutional ownership; BLACKROCK INC., holding 11,397,548 shares of the stock with an approximate value of $57.67 million in AKBA stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $40.1 million in AKBA stock with ownership of nearly 8.938% of the company’s market capitalization.
Positions in Akebia Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 86 institutional holders increased their position in Akebia Therapeutics Inc. [NASDAQ:AKBA] by around 34,449,663 shares. Additionally, 101 investors decreased positions by around 41,806,322 shares, while 25 investors held positions by with 24,231,429 shares. The mentioned changes placed institutional holdings at 100,487,414 shares, according to the latest SEC report filing. AKBA stock had 24 new institutional investments in for a total of 10,801,665 shares, while 55 institutional investors sold positions of 35,219,640 shares during the same period.